Provided by Tiger Trade Technology Pte. Ltd.

Anavex Life Sciences

4.20
-0.0600-1.41%
Post-market: 4.360.1602+3.81%18:45 EDT
Volume:1.58M
Turnover:6.60M
Market Cap:389.22M
PE:-9.08
High:4.32
Open:4.20
Low:4.06
Close:4.26
52wk High:13.99
52wk Low:2.86
Shares:92.67M
Float Shares:83.05M
Volume Ratio:1.79
T/O Rate:1.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4626
EPS(LYR):-0.5438
ROE:-33.63%
ROA:-21.56%
PB:3.07
PE(LYR):-7.72

Loading ...

BRIEF-Anavex Life Sciences Appoints Senior Vice President Global Head Of Neurology

Reuters
·
Jan 08

Anavex Life Sciences Appoints Wolfgang Liedtke as Senior Vice President, Global Head of Neurology

Reuters
·
Jan 08

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 06

Anavex Life Sciences Corp - Discussion on Potential Pathways for Nda for Alzheimer's Treatment

THOMSON REUTERS
·
Jan 06

Anavex Life Sciences Corp: Existing Data From Phase Iib/Iii Anavex2-73-Ad-004 Program Requested by Agency Will Be Submitted

THOMSON REUTERS
·
Jan 06

Anavex Life Sciences Corp - FDA Shows Interest in Anavex's Development Plans

THOMSON REUTERS
·
Jan 06

Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program

GlobeNewswire
·
Jan 06

Anavex Life Sciences Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 22, 2025

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 19, 2025

Anavex Life Sciences Corp - Requests Ema to Re-Examine Blarcamesine for Alzheimer's

THOMSON REUTERS
·
Dec 18, 2025

Anavex Life Sciences Requests EMA Re-Examination of Alzheimer's Drug Blarcamesine

Reuters
·
Dec 18, 2025

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 15, 2025

EU Regulator Rejects Anavex Alzheimer's Drug Application

Reuters
·
Dec 13, 2025

Anavex Life Sciences Corp - Chmp Adopts Negative Opinion on Blarcamesine for Alzheimer's

THOMSON REUTERS
·
Dec 13, 2025

Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease

THOMSON REUTERS
·
Dec 13, 2025

Anavex Life Sciences Up Nearly 21%, on Pace for Largest Percent Increase Since December 2024 -- Data Talk

Dow Jones
·
Dec 04, 2025

Anavex Life Sciences Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
Nov 28, 2025

Anavex Life Sciences: Navigating Legal Risks and Regulatory Challenges in a High-Stakes Industry

TIPRANKS
·
Nov 27, 2025

Anavex Life Sciences Earnings Call: Mixed Sentiments and Future Prospects

TIPRANKS
·
Nov 27, 2025

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 27, 2025